SecurityWLH / Lyon William Homes (552074700)
IndustryOperative Builders
Common Shares Outstanding34,267,510 shares (as of 2017-12-31)
Total Insiders18
Total Directors8
Total Officers7

Stock Insider Trading (from SEC Form 4)

Lyon William Homes insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

WLH / Lyon William Homes insiders include Luxor Capital Partners, LP, GMT CAPITAL CORP, ROBINSON RICHARD S Luxor Wavefront, LP, DOYLE BRIAN W, SEVERN COLIN T, LYON WILLIAM H, SCHELL LYNN CARLSON, Paulson Property Management II LLC, and LCG HOLDINGS LLC, LYON WILLIAM, HARRISON THOMAS F, Ammerman Douglas K, Luxor Capital Group, LP, LILJESTROM JASON R, NIEMANN MATTHEW R, Hunt Gary H, ZAIST MATTHEW R, .

Insider Roster

Insider Dir Off 10% Shares Owned
DOYLE BRIAN W EVP & COO
X 166,856
SEVERN COLIN T SVP & Chief Financial Officer
X 97,207
LILJESTROM JASON R SVP Gen. Counsel & Secretary
X 45,669
ZAIST MATTHEW R President & CEO, Director
X X 415,938
LYON WILLIAM H Executive Chairman, Director, 10% Owner
X X X 299,649
NIEMANN MATTHEW R Director
X 43,963
Hunt Gary H Director
X 34,446
HARRISON THOMAS F Director
X 21,314
SCHELL LYNN CARLSON Director
X 57,644
Ammerman Douglas K Director
X 50,246
GMT CAPITAL CORP 10% Owner
X 3,495,417
Paulson Property Management II LLC 10% Owner
X 0
LYON WILLIAM Executive Chairman, Director
X X
Luxor Capital Group, LP 10% Owner
Luxor Capital Partners, LP 10% Owner
Luxor Wavefront, LP 10% Owner
LCG HOLDINGS LLC 10% Owner
X
ROBINSON RICHARD S SVP of Finance & Acquisition
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-04-04 4 DOYLE BRIAN W S X D 28.0191 -15,596 166,856 4,675,155
2018-03-01 4 LYON WILLIAM H F D 25.28 -43,961 299,649
2018-03-01 4 ZAIST MATTHEW R F D 25.28 -50,050 415,938
2018-03-01 4 DOYLE BRIAN W F D 25.28 -18,681 182,452
2018-03-01 4 LILJESTROM JASON R F D 25.28 -5,389 45,669
2018-03-01 4 SEVERN COLIN T F D 25.28 -13,756 97,207
2018-02-22 4 DOYLE BRIAN W A D 12,714 201,133
2018-02-22 4 LILJESTROM JASON R A D 5,722 51,058
2018-02-22 4 LYON WILLIAM H A D 15,891 343,610
2018-02-22 4 SEVERN COLIN T A D 8,581 110,963
2018-02-22 4 ZAIST MATTHEW R A D 27,334 465,988
2018-02-22 4 Ammerman Douglas K A D 4,195 50,246
2018-02-22 4 SCHELL LYNN CARLSON A D 4,195 57,644
2018-02-22 4 HARRISON THOMAS F A D 4,195 21,314
2018-02-22 4 Hunt Gary H A D 5,148 34,446
2018-02-22 4 NIEMANN MATTHEW R A D 4,195 43,963
2018-02-15 4 DOYLE BRIAN W A D 48,650 188,419
2018-02-15 4 LILJESTROM JASON R A D 22,702 45,336
2018-02-15 4 LYON WILLIAM H A D 111,848 327,719
2018-02-15 4 SEVERN COLIN T A D 44,219 102,382
2018-02-15 4 ZAIST MATTHEW R A D 137,251 438,654
2018-01-29 4 GMT CAPITAL CORP S D 29.23 -34,300 3,495,417 102,171,039
2018-01-22 4 GMT CAPITAL CORP S D 32.13 -41,600 3,529,717 113,409,807
2018-01-16 4 GMT CAPITAL CORP S D 31.76 -44,700 3,571,317 113,425,028
2018-01-05 4 GMT CAPITAL CORP S D 30.99 -31,200 3,616,017 112,060,367
2018-01-02 4 GMT CAPITAL CORP S D 29.18 -31,200 3,647,217 106,425,792
2017-12-21 4 GMT CAPITAL CORP S D 28.38 -6,049 3,678,417 104,393,474
2017-12-18 4 GMT CAPITAL CORP S D 28.51 -11,620 3,684,466 105,044,126
2017-12-18 4 GMT CAPITAL CORP S D 29.03 -23,931 3,696,086 107,297,377
2017-12-13 4 GMT CAPITAL CORP S D 28.36 -5,100 3,720,017 105,499,682
2017-12-12 4 GMT CAPITAL CORP S D 28.73 -6,493 3,725,117 107,022,611
2017-12-11 4 GMT CAPITAL CORP S D 28.85 -19,607 3,731,610 107,656,948
2017-11-28 4 Hunt Gary H S D 29.3344 -2,500 29,298 859,439
2017-11-28 4 SEVERN COLIN T S D 29.264 -7,500 58,163 1,702,082
2017-11-17 4 ZAIST MATTHEW R By LLC S I 28.8289 -25,000 301,403 8,689,117
2017-09-18 4 Paulson Property Management II LLC See S I 23.81 -3,322,666 0
2017-09-11 4 GMT CAPITAL CORP S D 24.35 -41,600 3,751,217 91,342,134
2017-08-25 4 Hunt Gary H S D 22.8705 -8,500 31,798 727,236
2017-08-08 4 GMT CAPITAL CORP S D 23.09 -36,550 3,792,817 87,576,145
2017-08-07 4 GMT CAPITAL CORP S D 22.7 -15,450 3,829,367 86,926,631
2017-08-01 4 GMT CAPITAL CORP S D 22.74 -10,563 3,844,817 87,431,139
2017-07-31 4 GMT CAPITAL CORP S D 22.74 -10,237 3,855,380 87,671,341
2017-07-26 4 GMT CAPITAL CORP S D 23.38 -1,700 3,865,617 90,378,125
2017-07-25 4 GMT CAPITAL CORP S D 23.41 -34,959 3,867,317 90,533,891
2017-07-24 4 GMT CAPITAL CORP S D 23.29 -15,341 3,902,276 90,884,008
2017-07-19 4 GMT CAPITAL CORP S D 23.58 -16,422 3,917,617 92,377,409
2017-07-18 4 GMT CAPITAL CORP S D 23.37 -14,178 3,934,039 91,938,491
2017-07-17 4 GMT CAPITAL CORP S D 23.87 -16,200 3,948,217 94,243,940
2017-07-10 4 GMT CAPITAL CORP S D 23.86 -52,000 3,964,417 94,590,990
2017-07-07 4 GMT CAPITAL CORP S D 23.38 -1,527 4,016,417 93,903,829
2017-07-06 4 GMT CAPITAL CORP S D 23.33 -15,179 4,017,944 93,738,634
2017-07-05 4 GMT CAPITAL CORP S D 23.53 -30,669 4,033,123 94,899,384
2017-07-03 4 GMT CAPITAL CORP S D 23.53 -30,669 4,033,123 94,899,384
2017-06-27 4 GMT CAPITAL CORP S D 23.7 -1,736 4,068,417 96,421,483
2017-06-26 4 GMT CAPITAL CORP S D 23.5 -50,264 4,070,153 95,648,596
2017-06-20 4 GMT CAPITAL CORP S D 22.89 -14,900 4,120,417 94,316,345
2017-06-19 4 GMT CAPITAL CORP S D 22.55 -37,100 4,135,317 93,251,398
2017-06-13 4 GMT CAPITAL CORP S D 22.59 -32,300 4,172,417 94,254,900
2017-06-12 4 GMT CAPITAL CORP S D 22.52 -19,700 4,204,717 94,690,227
2017-06-08 4 GMT CAPITAL CORP S D 22.59 -9,991 4,224,417 95,429,580
2017-06-07 4 GMT CAPITAL CORP S D 22.65 -8,489 4,234,408 95,909,341
2017-06-06 4 GMT CAPITAL CORP S D 22.48 -21,513 4,242,897 95,380,325
2017-06-05 4 GMT CAPITAL CORP S D 22.84 -12,007 4,264,410 97,399,124
2017-05-31 4 GMT CAPITAL CORP S D 22.4 -40,828 4,276,417 95,791,741
2017-05-30 4 GMT CAPITAL CORP S D 22.66 -11,172 4,317,245 97,828,772
2017-05-23 4 GMT CAPITAL CORP S D 23.33 -23,349 4,328,417 100,981,969
2017-05-22 4 GMT CAPITAL CORP S D 23.39 -28,651 4,351,766 101,787,807
2017-05-15 4 GMT CAPITAL CORP S D 23.44 -52,000 4,380,417 102,676,974
2017-05-09 4 GMT CAPITAL CORP S D 23.16 41,968 4,432,417 102,654,778
2017-05-08 4 GMT CAPITAL CORP S D 22.1 10,032 4,474,385 98,883,908
2017-05-01 4 GMT CAPITAL CORP S D 21.99 -52,000 4,484,417 98,612,330
2017-04-24 4 GMT CAPITAL CORP S D 21.83 -52,000 4,536,417 99,029,983
2017-03-14 4 GMT CAPITAL CORP S D 19.6 -12,543 4,588,417 89,932,973
2017-03-13 4 GMT CAPITAL CORP S D 19.86 -39,457 4,600,960 91,375,066
2017-03-01 4 SEVERN COLIN T F D 18.43 -6,744 67,400
2017-03-01 4 ZAIST MATTHEW R F D 18.43 -19,416 326,403
2017-03-01 4 DOYLE BRIAN W F D 18.43 -7,884 139,769
2017-03-01 4 LILJESTROM JASON R F D 18.43 -2,462 22,634
2017-02-24 4 SEVERN COLIN T A D 12,624 74,144
2017-02-24 4 LILJESTROM JASON R A D 6,482 25,096
2017-02-24 4 DOYLE BRIAN W A D 13,890 147,653
2017-02-24 4 LYON WILLIAM H A D 31,931 215,871
2017-02-24 4 ZAIST MATTHEW R A D 39,182 345,819
2017-02-24 4 HARRISON THOMAS F A D 5,555 17,119
2017-02-24 4 SCHELL LYNN CARLSON A D 5,555 53,449
2017-02-24 4 Hunt Gary H A D 6,944 40,298
2017-02-24 4 Ammerman Douglas K A D 11,666 46,051
2017-02-24 4 NIEMANN MATTHEW R A D 5,555 39,768
2017-02-21 4 LYON WILLIAM H A D 41,578 183,940
2017-02-21 4 ZAIST MATTHEW R A D 46,198 306,637
2017-02-21 4 SEVERN COLIN T A D 14,629 61,520
2017-02-21 4 DOYLE BRIAN W A D 14,751 133,763
2017-02-21 4 LILJESTROM JASON R A D 5,900 18,614
2017-01-03 4 GMT CAPITAL CORP S D 19.03 -166,330 4,640,417 88,307,136
2016-12-29 4 GMT CAPITAL CORP S D 19.69 26,570 4,806,747 94,644,848
2016-08-12 4 GMT CAPITAL CORP P D 15.94 62,400 4,833,317 77,043,073
2016-06-07 4 GMT CAPITAL CORP P D 16.39 208,000 4,770,917 78,195,330
2016-05-16 4 GMT CAPITAL CORP P D 14.3 436,100 4,562,917 65,249,713
2016-04-11 4 GMT CAPITAL CORP P D 14.27 72,700 4,126,817 58,889,679
2016-03-31 4 GMT CAPITAL CORP P D 14.21 982,894 3,881,392 55,154,580
2016-04-04 4 GMT CAPITAL CORP P D 14.27 172,725 4,054,117 57,852,250
2016-03-22 4 Ammerman Douglas K A D 6,484 34,385
2016-03-22 4 Hunt Gary H A D 8,285 33,354
2016-03-22 4 SEVERN COLIN T A D 8,555 48,300
2016-03-22 4 NIEMANN MATTHEW R A D 6,484 34,213
2016-03-22 4 SCHELL LYNN CARLSON A D 12,247 47,894
2016-03-22 4 ZAIST MATTHEW R A D 27,017 260,439
2016-03-22 4 HARRISON THOMAS F A D 7,564 11,564
2016-03-22 4 LILJESTROM JASON R A D 6,484 12,714
2016-03-22 4 LYON WILLIAM H A D 24,315 142,362
2016-03-01 4 SEVERN COLIN T F D 11.86 -5,586 39,745
2016-03-01 4 ZAIST MATTHEW R F D 11.86 -10,222 233,422
2016-03-01 4 ZAIST MATTHEW R BY LLC F I 11.86 -6,698 233,422
2016-03-01 4 LILJESTROM JASON R F D 11.86 -1,255 6,230
2016-03-01 4 LYON WILLIAM H F D 11.86 -8,038 118,047
2016-02-24 4 LYON WILLIAM A D 9,999 74,008
2016-02-24 4 SEVERN COLIN T A D 9,749 45,331
2016-02-24 4 ZAIST MATTHEW R A D 25,499 250,342
2016-02-24 4 LILJESTROM JASON R A D 2,499 7,485
2016-02-24 4 LYON WILLIAM H A D 26,999 126,085
2015-12-16 4 LYON WILLIAM P D 15.6946 6,000 64,009 1,004,596
2015-12-11 4 LYON WILLIAM P D 15.3997 33,000 58,009 893,321
2015-11-19 4 ZAIST MATTHEW R BY LLC P I 16.11 5,000 127,724 2,057,634
2015-11-19 4 ZAIST MATTHEW R P D 16.11 1,000 97,119 1,564,587
2015-11-17 4 Hunt Gary H P D 15.9961 1,840 25,069 401,006
2015-08-19 4 Luxor Capital Group, LP By Separately Managed Account S I 23.7500 -36,617 37,315 886,231
2015-08-19 4 Luxor Capital Group, LP By Thebes B Onshore, LLC S I 23.7500 -10,901 16,013 380,309
2015-08-19 4 Luxor Capital Group, LP By Luxor Capital II Company LLC S I 23.7500 -1,278,215 700,000 16,625,000
2015-08-19 4 Luxor Capital Group, LP By Luxor Wavefront, LP S I 23.7500 -105,376 285,799 6,787,726
2015-08-19 4 Luxor Capital Group, LP By Luxor Capital Partners, LP S I 23.7500 -568,891 1,355,661 32,196,949
2015-03-13 4 Hunt Gary H S D 22.8664 -5,363 23,229 531,164
2015-03-13 4 ZAIST MATTHEW R M D 8.6625 9,883 218,843
2015-03-11 4 SEVERN COLIN T F D 21.99 -584 49,767
2015-03-11 4 SEVERN COLIN T M D 8.6625 1,482 50,351
2015-03-06 4 ROBINSON RICHARD S S D 22.4692 -3,042 18,454 414,647
2015-03-06 4 ROBINSON RICHARD S S D 22.4836 -4,040 21,496 483,307
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...